Sensipar FDA Approval History
FDA Approved: Yes (First approved March 8, 2004)
Brand name: Sensipar
Generic name: cinacalcet
Dosage form: Tablets
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism, Hypercalcemia of Malignancy
Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Development timeline for Sensipar
|Mar 8, 2004||Approval Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.